Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELUT OTCMKTS:OTLC NASDAQ:SLGL NYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELUTElutia$1.36-8.1%$2.08$1.32▼$5.12$56.65M0.8947,041 shs360,594 shsOTLCOncotelic Therapeutics$0.05+10.3%$0.05$0.02▼$0.07$22.59M-0.77107,295 shs21,115 shsSLGLSol-Gel Technologies$24.04-7.3%$15.03$4.01▼$30.00$67.07M1.2623,812 shs14,618 shsXTNTXtant Medical$0.61-1.8%$0.63$0.33▼$0.78$80.02M-0.15120,731 shs38,364 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELUTElutia-21.54%-31.71%-26.62%-26.62%-64.11%OTLCOncotelic Therapeutics-10.69%-11.36%-1.68%-17.02%+103.48%SLGLSol-Gel Technologies-5.88%+10.91%+62.16%+274.71%+347.07%XTNTXtant Medical+1.99%-0.40%+0.81%-7.08%+10.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELUTElutia$1.36-8.1%$2.08$1.32▼$5.12$56.65M0.8947,041 shs360,594 shsOTLCOncotelic Therapeutics$0.05+10.3%$0.05$0.02▼$0.07$22.59M-0.77107,295 shs21,115 shsSLGLSol-Gel Technologies$24.04-7.3%$15.03$4.01▼$30.00$67.07M1.2623,812 shs14,618 shsXTNTXtant Medical$0.61-1.8%$0.63$0.33▼$0.78$80.02M-0.15120,731 shs38,364 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELUTElutia-21.54%-31.71%-26.62%-26.62%-64.11%OTLCOncotelic Therapeutics-10.69%-11.36%-1.68%-17.02%+103.48%SLGLSol-Gel Technologies-5.88%+10.91%+62.16%+274.71%+347.07%XTNTXtant Medical+1.99%-0.40%+0.81%-7.08%+10.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELUTElutia 3.00Buy$8.00490.41% UpsideOTLCOncotelic Therapeutics 0.00N/AN/AN/ASLGLSol-Gel Technologies 0.00N/AN/AN/AXTNTXtant Medical 3.00Buy$1.50144.30% UpsideCurrent Analyst Ratings BreakdownLatest OTLC, ELUT, XTNT, and SLGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $6.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELUTElutia$24.38M2.36N/AN/A($1.31) per share-1.03OTLCOncotelic Therapeutics$70K322.70$0.01 per share10.21$0.02 per share2.58SLGLSol-Gel Technologies$11.54M5.81N/AN/A$10.36 per share2.32XTNTXtant Medical$117.27M0.68N/AN/A$0.31 per share1.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELUTElutia-$53.95M-$1.06N/AN/AN/A-90.01%N/A-54.08%11/13/2025 (Estimated)OTLCOncotelic Therapeutics-$4.52M-$0.01N/A∞N/AN/A-9.62%-2.72%N/ASLGLSol-Gel Technologies-$10.58M-$1.23N/AN/AN/A-14.25%-11.80%-9.39%11/14/2025 (Estimated)XTNTXtant Medical-$16.45M-$0.13N/A∞N/A-3.59%-10.12%-4.67%11/12/2025 (Estimated)Latest OTLC, ELUT, XTNT, and SLGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025SLGLSol-Gel Technologies-$0.67$4.17+$4.84$4.17$2.86 million$17.26 million8/14/2025Q2 2025ELUTElutia-$0.17-$0.26-$0.09-$0.26$6.55 million$6.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELUTElutiaN/AN/AN/AN/AN/AOTLCOncotelic TherapeuticsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELUTElutiaN/A0.590.45OTLCOncotelic TherapeuticsN/A0.010.01SLGLSol-Gel TechnologiesN/A7.327.32XTNTXtant Medical0.462.471.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELUTElutia74.03%OTLCOncotelic TherapeuticsN/ASLGLSol-Gel Technologies26.18%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipELUTElutia27.60%OTLCOncotelic Therapeutics39.22%SLGLSol-Gel Technologies66.51%XTNTXtant Medical9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELUTElutia18042.40 million30.69 millionNot OptionableOTLCOncotelic Therapeutics20437.77 million266.08 millionNot OptionableSLGLSol-Gel Technologies502.79 million933,000OptionableXTNTXtant Medical120130.32 million117.68 millionNot OptionableOTLC, ELUT, XTNT, and SLGL HeadlinesRecent News About These CompaniesXtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200-Day Moving Average - Should You Sell?September 8 at 3:09 AM | marketbeat.comXtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | prnewswire.comXtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200-Day Moving Average - Here's WhyAugust 31, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above Two Hundred Day Moving Average - Should You Sell?August 23, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above 200-Day Moving Average - Should You Sell?August 14, 2025 | marketbeat.comEarnings To Watch: Xtant Medical Holdings Inc (XTNT) Reports Q2 2025 ResultAugust 13, 2025 | finance.yahoo.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comXtant Medical Reports Strong Q2 2025 ResultsAugust 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | finanznachrichten.deXtant Medical Holdings, Inc. (XTNT) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comXtant Medical Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | prnewswire.comEarnings Preview For Xtant Medical HldgsAugust 11, 2025 | benzinga.comXtant Medical to Attend the CG 45th Annual Growth ConferenceAugust 6, 2025 | prnewswire.comXtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025August 5, 2025 | prnewswire.comXtant Medical Partners With B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market OpportunityJuly 29, 2025 | finance.yahoo.comXtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion SpineJuly 8, 2025 | prnewswire.comXtant Medical Holdings Inc Share Price (XTNT.US)June 4, 2025 | lse.co.ukXtant Medical Announces the Launch of OsteoFactor Pro™May 28, 2025 | prnewswire.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deXtant Medical Holdings Inc (XTNT) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLC, ELUT, XTNT, and SLGL Company DescriptionsElutia NASDAQ:ELUT$1.36 -0.12 (-8.14%) As of 01:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Oncotelic Therapeutics OTCMKTS:OTLC$0.05 +0.00 (+10.26%) As of 11:26 AM EasternOncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.Sol-Gel Technologies NASDAQ:SLGL$24.04 -1.89 (-7.29%) As of 01:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Xtant Medical NYSEAMERICAN:XTNT$0.61 -0.01 (-1.76%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
